An engaging 3.5-day event not to be missed!
SOHO is a global society designed specifically for clinicians, research scientists and related health care professionals who specialize in the research and treatment of patients with hematologic malignancies. SOHO’s mission is to expedite worldwide research and education through the exchange of scientific information.
SOHO represents physicians and other professionals from all corners of the world. SOHO is leading vital efforts to further treatments for those with hematologic malignancies. Become a SOHO Member free-of-charge. Join us and experience the benefits of membership.
The Society of Hematologic Oncology (SOHO) holds its annual meeting during the September timeframe of each year in Houston, Texas. Note that SOHO members receive a 40% discount on registration fees. We expect approximately 2,500 hematologic oncology specialists to participate in the upcoming Tenth Annual Meeting of the Society (SOHO 2022). Click for more information and registration.
The Ambassador Program was created to increase geographical diversity and promote international understanding among hematologic oncology experts around the world. If you are interested, Contact us!
The EMA opinion is based on results from the phase I/II ZUMA-3 study of adults with R/R ALL
The chemotherapy-free treatment mobilized leukemia cells to peripheral circulation and led to “encouraging rates of response” in patients with R/R FLT3/ITD-mutated AML.
A study in Spain showed that CAR-T therapy is superior to the previous standard of care for patients with refractory DLBCL.
The EMA’s recommendation is based on results from the phase I/II MajesTEC-1 study evaluating the safety and efficacy of teclistamab in adults with R/R MM.
With this approval for the extension of the selinexor indication in the EU, the conditional marketing authorization is now converted to a full approval.
The FDA has granted Fast Track Designation and Rare Pediatric Disease Designation for WU-CART-007 for the treatment of R/R T-ALL and ALL.
The phase III TRANSFORM trial demonstrated the superiority of liso-cel as a second-line treatment for early R/R LBCL.
"Very interesting and exciting to share ideas and data with other hem/onc clinicians and scientists from around the world" –Prof. Dieter Hoelzer, founding member